These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 9876576)

  • 1. Critical dissolution tests of oral systems based on statistically designed experiments. II. In vitro optimization of screened variables on ER-coated spheres for the establishment of an in vitro/in vivo correlation.
    Abuzarur-Aloul R; Gjellan K; Sjölund M; Graffner C
    Drug Dev Ind Pharm; 1998 Mar; 24(3):203-12. PubMed ID: 9876576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical dissolution tests of oral systems based on statistically designed experiments. III. In vitro/in vivo correlation for multiple-unit capsules of paracetamol based on PLS modeling.
    Abuzarur-Aloul R; Gjellan K; Sjölund M; Graffner C
    Drug Dev Ind Pharm; 1998 Apr; 24(4):371-83. PubMed ID: 9876598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method.
    Qiu Y; Garren J; Samara E; Cao G; Abraham C; Cheskin HS; Engh KR
    J Pharm Sci; 2003 Nov; 92(11):2317-25. PubMed ID: 14603516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations of remoxipride and the gastrointestinal transit of 111In-marked extended-release coated spheres.
    Graffner C; Wagner Z; Nilsson MI; Widerlöv E
    Pharm Res; 1990 Jan; 7(1):54-8. PubMed ID: 2137217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated dissolution rate analysis (ACDRA) for controlled release drugs. Application to Roxiam.
    Zackrisson G; Ostling G; Skagerberg B; Anfält T
    J Pharm Biomed Anal; 1995 Apr; 13(4-5):377-83. PubMed ID: 9696546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
    Jantratid E; De Maio V; Ronda E; Mattavelli V; Vertzoni M; Dressman JB
    Eur J Pharm Sci; 2009 Jun; 37(3-4):434-41. PubMed ID: 19491035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo validation of the release rate and palatability of remoxipride-modified release suspension.
    Sjöqvist R; Graffner C; Ekman I; Sinclair W; Woods JP
    Pharm Res; 1993 Jul; 10(7):1020-6. PubMed ID: 8378244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of different variables on the in vitro dissolution of a theophylline sustained-release preparation].
    Fuchs WS; Jakobs R; Grunenberg P; Weiss G; Profitlich T; von Nieciecki A; Klemm FH; Laicher A; Stanislaus F
    Arzneimittelforschung; 1998 May; 48(5A):552-6. PubMed ID: 9676343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling.
    Meulenaar J; Keizer RJ; Beijnen JH; Schellens JH; Huitema AD; Nuijen B
    J Pharm Sci; 2014 Feb; 103(2):478-84. PubMed ID: 24311366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.
    Franek F; Jarlfors A; Larsen F; Holm P; Steffansen B
    Eur J Pharm Sci; 2015 Sep; 77():303-13. PubMed ID: 26091569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro-in vivo correlation for nevirapine extended release tablets.
    Macha S; Yong CL; Darrington T; Davis MS; MacGregor TR; Castles M; Krill SL
    Biopharm Drug Dispos; 2009 Dec; 30(9):542-50. PubMed ID: 19876936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroral sustained-release film-coated pellets as a means to overcome physicochemical and biological drug-related problems. I. In vitro development and evaluation.
    Amighi K; Timmermans J; Puigdevall J; Baltes E; Moës AJ
    Drug Dev Ind Pharm; 1998 Jun; 24(6):509-15. PubMed ID: 9876616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolution test for site-specific release isoniazid pellets in USP apparatus 3 (reciprocating cylinder): optimization using response surface methodology.
    Joshi A; Pund S; Nivsarkar M; Vasu K; Shishoo C
    Eur J Pharm Biopharm; 2008 Jun; 69(2):769-75. PubMed ID: 18191554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of vibration and agitation speed on dissolution of USP prednisone tablets RS and various IR tablet formulations.
    Seeger N; Lange S; Klein S
    AAPS PharmSciTech; 2015 Aug; 16(4):759-66. PubMed ID: 26104919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC).
    Hayes S; Dunne A; Smart T; Davis J
    J Pharm Sci; 2004 Mar; 93(3):571-81. PubMed ID: 14762896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.